Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Bavarian Nordic News

Aktie
WKN:  917165 ISIN:  DK0015998017 US-Symbol:  BVNKF Branche:  Biotechnologie Land:  Dänemark
26,30 €
+0,06 €
+0,23%
08:21:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,97 Mrd. €
Streubesitz
70,67%
KGV
15,06
Nachhaltigkeits-Score
70 %
Index-Zuordnung
-

Bavarian Nordic News

31.07.25 - GlobeNewswire
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance
COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the ...
28.07.25 - dpa-AFX
AKTIE IM FOKUS: Evotec legen weiter zu - Positives Umfeld, Bavarian Nordic
FRANKFURT/KOPENHAGEN (dpa-AFX Broker) - Die Aktien von Evotec haben am Montag auf dem höchsten Stand seit Mitte Juni von positiven Nachrichten für die Branche profitiert. ...
28.07.25 - GlobeNewswire
Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ...
24.07.25 - GlobeNewswire
Rumours of a Potential Takeover Offer for Bavarian Nordic A/S
COPENHAGEN, Denmark, July 24, 2025 – Bavarian Nordic A/S (OMX: BAVA) has become aware of market rumours regarding a potential takeover offer for Bavarian Nordic A/S by a ...
22.07.25 - GlobeNewswire
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of ...
09.07.25 - GlobeNewswire
Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country
Recurring order from an undisclosed European country to strengthen public preparedness. Combined with other recent orders from non-​European countries, the Company has now ...
26.06.25 - GlobeNewswire
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women. The multi-​partner research project is aimed at expanding access to mpox ...
18.06.25 - GlobeNewswire
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total ...
12.06.25 - GlobeNewswire
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 – Bavarian Nordic A/S (OMX ...
09.05.25 - GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. ...
06.05.25 - GlobeNewswire
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines
Exercised options total USD 143.6 million Secures manufacturing and supply of freeze-​dried JYNNEOS ® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian ...
02.05.25 - GlobeNewswire
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
16.04.25 - GlobeNewswire
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. ...
16.09.24 - ARIVA.DE Redaktion
WHO erteilt grünes Licht für Mpox-Impfstoff von Bavarian Nordic
Die Weltgesundheitsorganisation (WHO) hat den Mpox-​Impfstoff von Bavarian Nordic, MVA-BN, für den weltweiten Einsatz präqualifiziert. Dies ermöglicht den Vereinten Nationen ...

Newssuche

Videos

newspaper
16.04.26 +3,58%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »